Fennec Pharmaceuticals to Participate in Upcoming Investor Conference
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference. The event will take place on November 19, 2024, at the Sheraton New York Times Square Hotel in New York City. The company's management team will be available for one-on-one meetings throughout the conference. Fennec Pharmaceuticals, a commercial stage specialty pharmaceutical company, will use this platform to engage with investors and present their business updates.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) ha annunciato la sua partecipazione alla 15ª Conferenza Annuale Craig-Hallum Alpha Select. L'evento si svolgerà il 19 novembre 2024, presso il Sheraton New York Times Square Hotel a New York City. Il team di gestione dell'azienda sarà disponibile per incontri individuali durante tutta la conferenza. Fennec Pharmaceuticals, un'azienda farmaceutica specializzata in fase commerciale, utilizzerà questa piattaforma per interagire con gli investitori e presentare gli aggiornamenti sulla loro attività.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) ha anunciado su participación en la 15ª Conferencia Anual Craig-Hallum Alpha Select. El evento tendrá lugar el 19 de noviembre de 2024, en el Sheraton New York Times Square Hotel en la ciudad de Nueva York. El equipo de gestión de la empresa estará disponible para reuniones uno a uno durante toda la conferencia. Fennec Pharmaceuticals, una empresa farmacéutica especializada en etapa comercial, utilizará esta plataforma para interactuar con los inversores y presentar actualizaciones sobre su negocio.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX)는 제15회 연례 Craig-Hallum Alpha Select 컨퍼런스에 참여한다고 발표했습니다. 이번 행사는 2024년 11월 19일에 뉴욕시의 Sheraton New York Times Square Hotel에서 열릴 예정입니다. 회사의 관리 팀은 컨퍼런스 기간 동안 개별 미팅을 위해 대기할 것입니다. Fennec Pharmaceuticals는 상업 단계의 전문 제약 회사로서 이 플랫폼을 활용하여 투자자와 소통하고 비즈니스 업데이트를 제공할 것입니다.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) a annoncé sa participation à la 15ème Conférence Annuelle Craig-Hallum Alpha Select. L'événement se déroulera le 19 novembre 2024, à l'hôtel Sheraton New York Times Square à New York. L'équipe de direction de l'entreprise sera disponible pour des réunions individuelles tout au long de la conférence. Fennec Pharmaceuticals, une entreprise pharmaceutique spécialisée en phase commerciale, utilisera cette plateforme pour dialoguer avec des investisseurs et présenter des mises à jour sur son activité.
Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) hat seine Teilnahme an der 15. jährlichen Craig-Hallum Alpha Select-Konferenz bekannt gegeben. Die Veranstaltung findet am 19. November 2024 im Sheraton New York Times Square Hotel in New York City statt. Das Management-Team des Unternehmens wird während der gesamten Konferenz für Einzelgespräche zur Verfügung stehen. Fennec Pharmaceuticals, ein spezialisiertes Pharmaunternehmen in der Handelsphase, wird diese Plattform nutzen, um mit Investoren in Kontakt zu treten und Neuigkeiten zu ihrem Geschäft vorzustellen.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event.
Conference Details:
Event: 15th Annual Craig-Hallum Alpha Select Conference
Date: November 19, 2024
Location: Sheraton New York Times Square Hotel, New York City
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate & Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When is Fennec Pharmaceuticals (FENC) participating in the Craig-Hallum Alpha Select Conference?
Where will the Craig-Hallum Conference featuring Fennec Pharmaceuticals (FENC) be held?
What type of investor meetings will Fennec Pharmaceuticals (FENC) offer at the Craig-Hallum Conference?
Which stock exchanges is Fennec Pharmaceuticals listed on?
